Akari Therapeutics, Plc Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
Akari Therapeutics, Plc (AKTX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $1.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-04-15.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2025-04-15
- Akari Therapeutics, Plc effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was $1.00K, a 75.00% decline from fiscal 2023.
- Akari Therapeutics, Plc effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was $4.00K, a 880.39% increase from fiscal 2022.
- Akari Therapeutics, Plc effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was $408.00.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month as first filed |
|---|---|---|
| 2024-12-31 | $1.00K 10-K · filed 2025-04-15 | |
| 2023-12-31 | $4.00K 10-K · filed 2025-04-15 | $4.00 10-K · filed 2024-03-29 |
| 2022-12-31 | $408.00 10-K · filed 2024-03-29 | $408.40K 20-F · filed 2023-05-01 |
| 2021-12-31 | $39.57K 20-F · filed 2023-05-01 | |
| 2020-12-31 | $81.00 20-F · filed 2023-05-01 | |
| 2019-12-31 | $161.54K 20-F · filed 2022-05-16 | |
| 2018-12-31 | $0.00 20-F · filed 2021-04-21 | |
| 2017-12-31 | -$6.71K 20-F · filed 2020-03-31 | |
| 2016-12-31 | -$130.06K 20-F · filed 2019-04-23 | |
| 2015-12-31 | -$225.75K 20-F · filed 2018-07-18 | $2.96M 10-K · filed 2016-03-23 |
| 2014-12-31 | $0.00 20-F · filed 2017-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |